万方数据
万方数据
万方数据
万方数据
临床规范使用新型抗凝药物
作者：邓文宁， 马长生
作者单位：首都医科大学附属北京安贞医院 心内科,北京市,100029
刊名：
中国循环杂志
英文刊名：Chinese Circulation Journal
年，卷(期)：2013,28(6)
1.Connolly SJ;Ezekowitz MD;Yusuf S Dabigatran versus warfarin in patients with atrial fibrillation 2009
2.Patel MR;Mahaffey KW;Garg J;et at Rivaroxaban versus warfarin in nonvalvulac atrial fibrillation 2011
3.Granger CB;Alexander JH;McMurray J J Apixaban versus warfarin in patients with atrial fibrillation 2011
4.Connolly SJ;Eikelboom J;Joyner C;et at Apixaban in patients with atrial fibrillation 2011
5.Connolly SJ;Wallentin L;Ezekowitz MD The long-term multicenter observational study of Dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study 2013
6.Camm AJ;Kirchhof P;Lip GY Guidelines for the management of atrial fibrillation:the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) 2010
7.Fuster V;Ryden LE;Cannom DS2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation:a report of the American College of Cardiology
Foundation/American Heart Association Task Force on pracfce guidelines 2011
8.Camm AJ;Lip GY;De Caterina R;et al 2012 focused update of the ESC guidelines for the management of atrial fibrillation:an update of the 2010 ESC guidelines for the management of atrial fibrillation Developed with the special contribution of the european heart rhythm association 2012
9.Heidbuchel H;Verhamme P;Alings M EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation:executive summary 2013
10.Eriksson BI;Dahl OE;Huo MH Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE Ⅱ*).A randomised,double-blind,non-inferiority trial 2011
11.Eriksson BI;Dahl OE;Rosencher N Oral dabigatran etexilate vs.subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement:the RE-MODEL randomized trial 2007
12.Ginsberg JS;Davidson BL;Comp PC Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery 2009
13.Eriksson BI;Borris LC;Friedman RJ Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty 2008
ssen MR;Davidson BL;Gallus A The efficacy and safety of apixaban,an oral,direct factor Xa inhibitor,as thromboprophylaxis in patients following total knee replacement 2007
15.Schulman S;Kearon C;Kakkar A Dabigatran versus warfarin in the treatment of acute venous thromboembolism 2009
16.Bauersachs R;Berkowitz SD;Brenner B Oral rivaroxaban for symptomatic venous thromboembolism 2010
17.Goldhaber SZ;Leizorovicz A;Kakkar AK Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients 2011
18.Schulman S Extended anticoagulation in venous thromboembolism 2013
19.Schulman S;Kearon C;Kakkar AK Extended use of dabigatran,warfarin,or placebo in venous thromboembolism 2013
20.Cohen AT;Spiro TE;Būller HR Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical
patients:MAGELLAN study protocol 2011
21.Agnelli G;Buller HR;Cohen A Apixaban for extended treatment of venous thromboembolism 2013
22.Kearon C;Akl EA;Comerota A J Antithrombotic therapy for WrE disease:Antithrombotic Therapy and Prevention of Thrombosis,9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines 2012
23.Mega JL;Braunwald E;Wiviott SD Rivaroxaban in patients with a recent acute coronary syndrome 2012
24.Oldgren J;Budaj A;Granger CB Dabigatran vs.placebo in patients with acute coronary syndromes on dual antiplatelet therapy:a randomized,double-blind,phase Ⅱ trial 2011
25.Alexander JH;Lopes RD;James S Apixahan with antiplatelet therapy after acute coronary syndrome 2011
本文链接：/Periodical_zgxhzz201306002.aspx。